EIN Presswire: VivaQuant, Inc. Named Finalist for 2021 Tekne Awards
VivaQuant selected as a finalist for the Tekne Medical Technology innovation award for its unique wearable arrhythmia monitor.
Minneapolis Star Tribune: VivaQuant is making an intriguing bet on equity crowdfunding
VivaQuant is not anything like the dozen or so Minnesota businesses that have sought funding directly from small investors in the last few years, a list dominated by small craft brewers. VivaQuant doesn’t aspire to be a successful small business.
VivaQuant Receives FDA 510k Clearance for its RX-1 Rhythm Express Arrhythmia Device
VivaQuant, a digital health company with powerful technology to accurately and efficiently identify and report cardiac arrhythmias, has received FDA clearance for its RX-1 wearable device.
VivaQuant algorithm shows 6-fold reduction in risk classification error relative to FDA published results
This study demonstrates that fully automated continuous beat to beat measurements over 24 hours can be obtained using the Rhythm Express software and used to discriminate multichannel ion block from pure hERG block.
VivaQuant Inks Collaboration with FDA to Improve Accuracy of Drug Cardiac Safety Assessment
VivaQuant has entered into a five-year collaboration with the FDA to research ways to improve cardiac safety assessment of medications. In this project, VivaQuant's advanced ECG processing tools will be used to derive continuous beat-to-beat measurements of cardiac electrical waves from preclinical and clinical ECG studies.
VivaQuant Technology Shows Promise for Improving Drug Safety Assessment Accuracy
VivaQuant MDSP technology was the subject of a recent manuscript published in The Journal of Pharmacological and Toxicological Methods (JPTM) titled "Comparison of one- and three-lead ECG to measure cardiac intervals and differentiate drug-induced multi-channel block".
WEBINAR: Improving Preclinical and Clinical Regulatory Submissions Through Enhanced ECG Interval and Arrhythmia Assessment
Experts in preclinical and clinical ECG safety assessment discuss how advances in arrhythmia detection and concentration effects modelling improve study outcomes.
VivaQuant Rhythm Express software demonstrates improved accuracy of cardiac safety assessment markers
Fully automated QT measurements, obtained from VivaQuant Rhythm Express software, with no human review or editing, were shown to improve accuracy of concentration effect models used in drug safety assessment by 22 percent
VivaQuant and DSI Announce Agreement
Arrangement allows researchers to use the unique VivaQuant algorithms on ECG signals acquired by DSI telemetry and wired acquisition technologies.
VivaQuant Releases AE-1010 Rhythm Express Software
The AE-1010 software provides powerful features and performance for fast, accurate, and efficient analysis and insightful reporting of ECG arrhythmias and intervals in pharmaceutical and medical device research